Mechanism Of Action

Mechanism of Action

video_preview_play_button

Synergistic Ratio

Fixed 1:5 molar ratio of daunorubicin and cytarabine has been shown to produce a synergistic effect in vitro3

Prolonged Delivery

Synergistic molar ratio maintained for a prolonged period of time – over 24 hours after administration3

High Concentration

Vyxeos liposomes accumulate and persist in the bone marrow in high concentrations3

Preferential Uptake

Vyxeos is preferentially taken up by leukaemia cells vs normal bone marrow cells3

References

  1. Tolcher AW, Mayer LD. Future Oncol 2018; 14(13):1317-32.
  2. Lancet JE et al. 2018. J Clin Oncol 2018. Published online ahead of print. doi: 10.1200/JCO.2017.77.6112
  3. VYXEOS Summary of product characteristics

 

 

ADVERSE EVENTS REPORTING

 

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

 

EURW-INTVYX-0020a(1) | September 2019